Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Gastrointestinal Neoplasms 2Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1

Interventions

Cisplatin 508Cyclophosphamide 360Carboplatin 352Radiotherapy 350Capecitabine 328Paclitaxel 324Oxaliplatin 323Gemcitabine 320Docetaxel 310Fluorouracil 282Drug Therapy 243apatinib 242Bevacizumab 228camrelizumab 214Etoposide 200Irinotecan 175Doxorubicin 175Leucovorin 161Dexamethasone 160sintilimab 142pembrolizumab 138Pemetrexed 136Cytarabine 136anlotinib 135toripalimab 130Neoadjuvant Therapy 122S 1 (combination) 120Vincristine 119Rituximab 116Radiosurgery 116

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Interventional × CGX1321 × Clear all
NCT02675946 2022-01-26

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

Curegenix Inc.

Phase 1 Unknown
72 enrolled
Gastrointestinal

Gastrointestinal Neoplasms

NCT03507998 2020-07-24

Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors

Curegenix Inc.

Phase 1 Unknown
39 enrolled
Gastrointestinal

Bile Duct Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡